PRINCETON, NJ – June 3, 2015 – Certara®, the global biosimulation technology-enabled drug development consultancy, today announced that it is endowing a new three-year, full-time position – the Certara Lecturer in Precision Dosing – at the Manchester Pharmacy School, The University of Manchester, England. This lectureship is intended to advance teaching and research into individual dose optimization modeling, and to demonstrate its application to cancer, pediatric, and biologic therapies.
This new lecturer will work closely with the clinical pharmacy, clinical pharmacology, and quantitative proteomics research groups at The University of Manchester to raise the profile of precision dosing within the university’s precision medicine initiative. This staff member will also lead post-graduate modeling and simulation programs.
“Our work with global biopharm companies and regulatory agencies demonstrates the advantages of using biosimulation to answer precision dosing questions for specific cohorts such as pediatric or geriatric patients, women who are pregnant, or patients with co-morbidities,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “Through this new academic collaboration with The University of Manchester, we expect to further the field and make precision dosing for all individuals a reality.”
“Precision medicine has the potential to improve dramatically the healthcare outcomes for individual patients around the world,” added Professor Kay Marshall B.Pharm., FRPharm.S., PhD., MBA, head of Manchester Pharmacy School. “We are delighted to have this opportunity to partner with Certara and help prepare our students for exciting pharmacometric careers by providing them with individual dose optimization modeling experience.”
This new lecturer will become a member of the Systems Pharmacology Group within Manchester Pharmacy School. The postholder will report to the Head of School and be mentored by Professor Amin Rostami, Pharm.D., Ph.D., professor of systems pharmacology at The University of Manchester, and Certara’s Chief Scientific Officer.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.